Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
Phase 1
Completed
- Conditions
- Glabellar Lines
- Registration Number
- NCT06212960
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Brief Summary
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0 At 4, 8, 12 week after the injection
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chung-Ang University Hosptial
🇰🇷Seoul, Korea, Republic of
Chung-Ang University Hosptial🇰🇷Seoul, Korea, Republic of